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Abstract
Problem: Necrotizing Enerocolitis (NEC) is one of the leading causes of morbidity and
mortality in neonatal intensive care units (NICU), affecting 7% to 14% of premature neonates
weighing less than 1500g (Lin et al., 2008). Healthcare costs for the treatment of NEC account
for roughly 20% of the 5 billion dollars spent on infants in the NICU annually (Gephart,
McGrath, Effken & Halpern, 2012). Nutritional supplements, such as probiotics, may be used
prophylactically to prevent NEC in this high-risk population.
Objective: A literature review was performed to examine which strains of probiotics show the
most potential in reducing the incidence of necrotizing enterocolitis.
Method: A literature review was performed using CINAHL, Science Citation Index, Science
Direct, Medline, Academic One file, PsychINFO, and PUBMED databases. Key words included
enterocolitis, Necrotizing*/PC OR NEC* AND probiotics*. After applying exclusion criteria, 9
articles remained for this review.
Results: A variety of probiotic strains used to reduce the incidence of NEC were identified,
along with inconsistent times of initiation, number of colony forming units and length of
treatment. The most commonly studied probiotic strains include Lactobacillus species,
Bifidobacterium species, and Saccharomyces species. After detailed analysis, it appears that a
combination of Bifidobacterium species and Lactobacillus species reduce the incidence of NEC
from an 8% (Fernández-Carrocera et. al, 2013) reduction up to 100% reduction in the incidence
of NEC (Braga, Pontes da Silva, Cabral de Lira, & Lima, 2011). These two species, when
combined, were more successful when compared to Saccharomyces species or Lactobacillus
species alone.
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Conclusion: Although there is positive support for the proactive use of probiotics for the
reduction of the incidence of NEC in premature neonates, the inconsistencies between studies are
a barrier for determination of a specific treatment recommendation. Although the combination of
Bifidobacterium species and Lactobacillus species has been shown to have an impact on the
reduction of NEC incidence, the research inconsistencies provide a barrier to generalizations for
treatment. Additional research that focus on Bifidobactrium species in combination with
Lactobacillus species is needed. Furthermore, the use of probiotics as a preventative treatment
for NEC has not been thoroughly researched in extremely premature infant populations (<28
weeks gestation). Therefore, although the results are promising, further research is needed before
this can be determined as a safe preventative method. The current questions remaining include:
when prophylactic treatment should be initiated, how long prophylactic treatment should last, the
number of colony forming units to be administered, and what is the long-term impact of
probiotic administration on the normal gut flora, if any.
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Introduction
Necrotizing Enerocolitis (NEC) is one of the leading causes of morbidity and mortality in
neonatal intensive care units (NICU), effecting 7% to 14% of premature neonates weighing less
than 1500g (Lin et al., 2008). A neonate is classified as premature when born before the 37th
week of gestation. Of the neonates suffering from NEC, it is estimated that roughly 30% will not
survive and although technological advances have improved care for increasingly premature
neonates, the incidence of NEC has not decreased in over 20 years (Gephart, et al., 2012; Neu,
Mshvildadze, &Mai, 2008). Treatment of NEC has a significant financial impact accounting for
roughly 20% of the 5 billion per year cost for all NICU treatment costs in the United States
(Gephart et al., 2012). The immediate treatment cost for a single neonate diagnosed with NEC
ranges between $73,000 and $182,000 depending on surgical needs. In addition to financial
hardship, neonates with NEC typically stay in the NICU 22 to 60 days longer than the average
NICU patient (Gephart et al., 2012). This prolonged stay in the NICU also generates an
emotional hardship on the family as well as disrupting early infant bonding.
Recent studies involving the use of probiotics have shown promising results in terms of
reducing the incidence of NEC (Thompsom & Bizzarro, 2008). The World Health Organization
defines probiotics as “live microorganisms which when administered in adequate amounts confer
a health benefit on the host” (World Health Organization [WHO], 2001). Further studies need to
be conducted to determine the most effective treatment plan including the optimal time of
initiation, length of time treatment is implemented, as well as the combination of probiotics used
for treatment.
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Background
Necrotizing Enterocolitis
Necrotizing Enterocolitis (NEC) is a multifactorial gastrointestinal (GI) disease in which
areas of a newborn’s bowel become necrotic (the tissue dies). In 2011, the National Healthcare
Safety Network (NHSN) updated the clinical and surgical criteria for the diagnosis of NEC.
These updated criteria stated that for an infant to be diagnosed with NEC based on clinical and
radiographic criteria, they must present with bilious aspirate, vomiting, abdominal distension, or
occult blood in stool, plus one or more of the following radiographic signs: pneumatosis
intestinalis, which is gas in the bowel wall, portal venous gas, or pneumoperitoneum (National
Healthcare Safety Network [NHSN], 2011). Furthermore, the surgical criteria for NEC are that
the infant must have more than two centimeters of necrotic bowel or surgical evidence of
pneumatosis intestinalis, with or without intestinal perforation (NHSN, 2011).
Prematurity
NEC is almost exclusively seen in preterm neonates (Sari, et al., 2011). An infant born
before the 37th week of gestation is considered premature. The presentation rate of necrotizing
enterocolitis is indirectly proportionate to the age of a neonate (Gephart et al., 2012). That is, the
earlier a neonate is born, the longer it will take for NEC to present. For example, the average
onset of NEC in a neonate born at the 28th week of gestation is 40 days, whereas the average
onset for a neonate born at 36 weeks is 5 days (Mayer, 2011).
Due to this near exclusive presentation, gut prematurity is believed to be a primary
inciting factor of the disease. The gastrointestinal tract is developed from all three of the
embryonic germ layers, the endoderm, mesoderm and ectoderm (Mayer, 2011). Development of
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the fetal gut is broken down into four distinct phases: formation of the endoderm, morphogenesis
and patterning of the gut tube, and organ morphogenesis and terminal differentiation (Mayer,
2011). While this maturation predominately takes place during the first trimester, the muscular
maturity and hormonal maturity that control motility does not begin until the second trimester
and continues until term (Braga et al., 2011). More significantly even, the “waves” of peristalsis
needed for elimination are not seen in their entirety until a gestational age of 33 to 34 weeks
(Braga et al, 2011). Therefore, gastric emptying is severely impaired for infants less than 32
weeks gestation. Due to the increased peristaltic waves seen at 33 weeks gestation, the majority
of research investigating NEC excludes infants older than 32 weeks gestation (Braga et al.,
2011). Despite this impaired gastric emptying, it is commonly suggested that enteral feeding
commence as soon as possible once an infant is clinically stable (Ayede, 2011) This prevents a
decrease in digestive enzymes as a result of mucosal and villous atrophy (Ayede, 2011).
The longitudinal and transverse muscles are responsible for the peristaltic action of the
bowels (Mayer, 2011). Peristalsis is a mechanism used by the intestines to remove digested food
and pathologic bacteria. Therefore, premature infants with immature intestinal smooth muscle
consequently have decreased gut motility. This decreased motility may lead to a build-up in
pathologic bacteria.
Bacterial Colonization
Gastrointestinal microbiota is a dynamic ecosystem with approximately 500 to 1000
differing species of bacteria that colonize the gastrointestinal tract of a healthy infant (Guaraldi,
F. & Salvatori, G., 2012). This gut microbiota influences the growth and differentiation of gut
epithelial cells and have a role immunologic and protective functions (Guaraldi, F. & Salvatori,
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G., 2012) Molecular studies have shown that the guts of healthy breast-fed and formula-fed
infants consist of 60% to 90% Bifidobactrium species with the most common strains of
Bifidobactrium being B. bifidium, B.longum,and B. breve (Lin et al., 2008). Another primary
physiologic bacterium are Lactobacillus species which have been shown to induce antiinflammatory cytokines such as interleukin 10 (Lin et al., 2008).
Studies demonstrate that the gut microbiota of a term breast-fed infant and a term
formula-fed infant have no significant differences (Guaraldi, F. & Salvatori, G., 2012). However,
it has been reported that breast-fed newborns have a more uniform and stable population of
bacteria and have two times the number of bacteria cells when compared to formula-fed
newborns (Bezirtzoglou, Tsiotsias, & Welling, 2011). It is consequently appropriate to
hypothesize that various strains of Bifidobacterium would have the greatest positive affect on
reducing the incidence of NEC.
While a neonate is in utero, the intestine is sterile, surrounded by amniotic fluid
(Guaraldi, F. & Salvatori, G., 2012). Bacterial colonization begins at birth and is influenced by
several external factors such as mode of delivery, vaginal, or cesarean section, the environment,
such as equipment, air and other people, and the ingestion of colostrum(the mother’s initial milk)
if the mother is breast feeding (Guaraldi, F. & Salvatori, G., 2012). During vaginal delivery, the
newborn comes into direct contact with the maternal vaginal and intestinal flora via the ocular,
nasal and oral cavities. This direct contact is absent in a cesarean section and gut bacteria is
derived primarily from environmental factors (Guaraldi, F. & Salvatori, G., 2012). For this
reason, vaginal delivery is associated with a greater biodiversity of healthy bacteria within the
newborn gut (Godhia, M.L. & Patel, N., 2013). Colostrum is rich in antibodies that give passive
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immunity to a newborn, growth factors that mature the gut epithelial cells, which prepare the
newborn for human milk or formula, and antimicrobial peptides (Godhia, et al., 2013).
Conversely, premature births are associated with higher rates of cesarean sections, hindered
ability to breastfeed, due to delayed onset of lactation (Neu, J. & Rushing, J., 2011), and the
newborn being surrounded with equipment in the NICU (Godhia, et al., 2013). These factors
alter the introduction of bacteria to the newborn and as a result the preterm gut is predominately
colonized by Staphlococccus, Enterobacter, Enterococcus, and Clostridia (Thompsom &
Bizzarro, 2008). These pathologic bacteria then compete with the natural gut flora for nutrients,
and if uncontrolled, an overabundance of pathologic bacteria can be a precursor to
gastrointestinal disease such as NEC.
At birth, even in an infant born at term, the immune system has not fully matured. The
adaptive immunity gains specificity into early childhood (Melville, J.M. & Moss, T., 2013).
Immaturity of the immune system is even more pronounced in the preterm infant (Melville, J.M.
& Moss, T., 2013). There is a reduced number of monocytes and neutrophils and a lower
productions of cytokines which reduces the preterm infant’s ability to recognize and kill
pathogens when compared to the term newborn (Melville, J.M. & Moss, T., 2013). Due to this
reduced ability to detect and neutralize bacteria and viruses, preterm infants are typically placed
on broad-spectrum antibiotic therapy to reduce the bacterial load their immune system faces
(Melville, J.M. & Moss, T., 2013). These antibiotics consequently further reduce the biodiversity
of the preterm gut bacteria. Pathologic bacteria within the gut accumulate due to both decreased
GI motility and these immunologic deficiencies.
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Broad-spectrum antibiotics are also administered to mothers who go into premature labor
or who have a cesarean section even prior to birth. This may also be a contributing factor that
reduces the biodiversity of gut microbiota in preterm infants (Neu, J. & Rushing, J., 2011).
Oxygenation
A third inciting factor believed to contribute to NEC is hypoxic-ischemic injury. Any
congenital or environmental factor that affects the oxygenation of the newborn, such as patent
ductus arteriosus, respiratory distress, or in utero cocaine exposure, can lead to hypoperfusion.
(Thompsom & Bizzarro, 2008). Decreased oxygenation and subsequent decreased organ
perfusion is a common problem in premature infants. This can be attributed to the immature lung
formation and lack of surfactant in the premature infant’s lungs. Surfactant production begins at
roughly 32 weeks gestation and reduces surface tension at the air-liquid junction of the alveolus
subsequently allowing the alveoli to expand to capacity to perfuse the capillaries surrounding the
alveoli (Nkadi, P., Merritt, T., & Pillers, D., 2009). To combat the lack of surfactant production,
preterm infants are treated with antenatal corticosteroids and exogenous surfactant upon birth
(Nkadi, P. et al., 2009). Without sufficient oxygen exchange between the lungs’ alveoli and the
blood there is hypo-oxygenation of organs throughout the body. During times of hypooxygenation, the body shunts blood to vital organs, such as the brain and heart, and away from
“non-vital” organs, such as the intestines (Thompsom & Bizzarro, 2008). This subsequent
decrease in oxygen to the gut causes a hypoxic-ischemic state. If the hypo-oxygenation is
reversed, reperfusion can cause a proinflammatory cascade leading to damaged mucosal barrier
by tumor necrosis factor α (TNF α) and platelet activating factor (Gephart et al., 2012).
Inflammation, which reduces cell membrane integrity, is likely to cause hyperpermeability of the
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intestinal wall, thus creating an opportunity for bacteria to permeate the gut lining. If bacteria
continues past the gut lining, into the peritoneal cavity, sepsis and death can occur (Gephart, et
al. 2012).
Diagnosis Necrotizing Enterocolitis
Diagnosis of NEC is oftentimes difficult due to its nonspecific clinical manifestations in
the early stages. Temperature instability is one of the most common early signs of NEC while
other signs may include apnea, low oxygen saturation, lethargy, and bradycardia (Thompsom &
Bizzarro, 2008). As the disease progresses, there may be GI specific manifestations, such as a
distended abdomen, feeding intolerance, and blood in the infant’s stool (Thompsom & Bizzarro,
2008). Common diagnostic tests include an abdominal x-ray and serum analysis. According to
Thompsom and Bizzarro (2008), radiographic signs of NEC may include dilated or fixed
intestinal loops, air in the intestinal wall or free air in the abdomen. Serum analysis may show
low platelet count and/or elevated white blood cells, although nonspecific, this is an indication of
infection (Thompsom & Bizzarro, 2008). Based upon the combination of these diagnostic tests,
the severity of NEC can be staged using the Bell’s criteria. Stages range from IA: Suspected to
IIIB: Advanced, severely ill, perforated bowel (Thompsom & Bizzarro, 2008).
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Figure 1: Bell's Classification of NEC
Stage

Classification

Intestinal Signs

Radiologic Signs

Systemic signs

IA

Suspected NEC

Decreased gastric
emptying,
abdominal
distention, emesis

Normal or
intestinal dilation

IB

Suspected NEC

Same as IA

IIA

Proven NEC-mild

IIB

Proven NECmoderate

IIIA

Advanced NECbowel intact
Requires surgery.

Bright red blood
from rectum.
Same as IA plus
absent bowel
sounds, with or
without abdominal
tenderness
Same as IIA with
definite abdominal
tenderness and
with or without
right lower
quadrant mass
Same as IIB with
generalized
peritonitis, marked
tenderness, and
distention of
abdomen

Temperature
instability,
apnea,
bradycardia,
lethargy
Same as IA

Same as IIIA

Same as IIB with
pneumoperitoneum

IIIB

Advanced NECbowel perforation
Requires Surgery.
Adapted from Lee & Polin, 2003

Intestinal dilation,
ileus, and
pneumatosis
intestinalis.

Same IA

Same as IIA plus
portal venous gas
with or without
ascites

Same as IA plus
mild metabolic
acidosis and
thrombocytopenia

Same as IIB with
definite ascites

Same as IIB with
hypotension,
bradycardia,
apnea, respiratory
and metabolic
acidosis and
neutropenia
Same as IIIA

Treatment of Necrotizing Enterocolitis
Treatment of NEC ranges from bowel rest for suspected NEC, the use of antibiotics along
with bowel rest for proven but mild NEC, to surgery for advanced NEC. When NEC progresses
into the “advanced” stages of NEC and requires surgery, it is termed “surgical NEC” and the
long-term prognosis for the infant decreases. Long-term ramifications of surgical NEC include
short bowel syndrome and neurodevelopment impairment (NDI) (Schulzle S.M., Desphande
G.C., & Patole SK, 2007). Due to its costly and deadly nature, an effective preventative strategy
needs to be further researched and implemented (Fanaroff, A. A. & Fanaroff J. M., 2013).
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There are multiple proposed strategies for the prevention of NEC. These strategies
include antenatal corticosteroids, which have been shown to mature the gut in a manner similar
to the mechanism enhancing lung maturation; trophic feedings in which small volumes of enteral
feedings are introduced in order to facilitate peristaltic action; oral antibacterials, in an effort to
reduce the number of pathogenic bacteria; and prebiotics, used to selectively increase the
population of commensal GI bacteria. And lastly, the use of probiotics, thought to be the most
promising of therapies, and the focus of this literature review (Thompsom & Bizzarro, 2008).
The Pharmacodynamics of Probiotics
The knowledge that a healthy newborn delivered at full term has a gut primarily
consisting of Bifidobactrium species (Lin et al., 2008), while the preterm newborn has a gut
microbiota consisting primarily of staphlococci, enterobacter, enterococci, and clostridia bacteria
(Thompsom & Bizzarro, 2008) led researchers to hypothesis that the use of probiotic
supplementation would decrease the incidence of NEC. Probiotics are dietary supplements that
introduce indigenous microbes to the human GI tract and confer a health benefit to the infant
(Janvier, Malo & Barrington, 2014). It has been recently supported in research that probiotics
“provide benefit to preterm neonates by enhancing the IgA mucosal response, improving the
mucosal protective barrier, increasing the production of anti-inflammatory cytokines, decreasing
intestinal wall permeability and competitively excluding pathogenic microbes” (Thompsom &
Bizzarro, 2008, pp. 1234).
The indigenous microbes in a healthy human GI tract also aid in the digestion of protein
and carbohydrates. Therefore, the administration of probiotics to preterm neonates could
potentially result in a decrease in the rate of NEC, increased feeding tolerance, and a reduced rate
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of sepsis. Of the studies investigating probiotics as a prevention strategy for NEC, the most
commonly studied species have been those that include Bifidobacteria, Lactobacillus, and
Saccharomyces (Thompsom & Bizzarro, 2008).
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Problem
Plateau in Incidence
Although technology and treatment options have expanded which has increased the ability
to care for and sustain increasingly premature infants, for example those born less than 28 weeks
gestation, the incidence of NEC has plateaued rather than declined. The reason for this plateau is
that the incidence of NEC is inversely proportional to gestational age. That is, there is a greater
number of infants who develop NEC at 32 weeks gestation than there are at 36 weeks gestations
(Gephart, et al. 2012). Due to this sustained occurrence rate recent research has shifted from
treatment to prevention.
Mortality
NEC is a devastating disease that is responsible for 20%-25% percent of preterm and low
birth weight deaths each year (Deshpande, G.C. Rao, S. Patole, S., & Bulsara, M., 2010).With this
being a disease that ranks as the second highest cause of death among NICU patients (Deshpande
et al., 2010), it is making its way to the forefront of neonatal research. However, there still remains
little knowledge as to the intricate details and microbiota of the disease.
Cost of Hospitalization
NEC poses a significant financial burden, accounting for 20% of all neonatal treatment at
nearly 5 billion dollars spent each year treating the disease (Gephart et al., 2012). It is estimated
that an infant diagnosed with NEC, will stay on average an extra 22 days longer in the hospital
than other infants of comparable gestational age (Gephart et al., 2012). Furthermore, the cost of
treating one infant with NEC has been reported to be as high $216,666 per survivor (Deshpande,
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et al., 2010). Research by Johnson and colleagues (2013) indicates that medically treated NEC,
which is stages 1 and 2 that do not require surgery, increased hospital direct costs by $13,136
(p=0.034) and surgically treated NEC, which is Stage 3 or “advanced NEC”, increased hospital
direct costs by $22,328 (p=0.039) when compared with infants without NEC of similar gestational
age, birth weight and demographics (Johnson, Patel, A., Jegier, Engstrom, & Meier, 2013). Directs
costs include all chargeable items such as electrolyte panel, room charges and medications, during
the infant’s hospital stay (Johnson et al., 2013). These increased costs can be attributed to not only
the increased length of hospital stay but also the additional care needs (Johnson et al., 2013). Given
this significant financial burden the benefits of a prophylactic treatment aimed at reducing NEC,
such as probiotics, is significant.
Lack of Research
There is a paucity of research and inconsistent methodologies amongst the current research
concerning probiotics and their ability to reduce NEC. Specifically, there has yet to be a study
design replicated to validate previously reported results. Without replicated studies that validate
the benefits of a particular probiotic strain, dosage or administration protocol, health professionals
are reluctant to implement the use of them in standard practice or recommend the use of probiotics
to caregivers with any guarantee.
Cost of Probiotics
Probiotics are neither drug nor device and they are unregulated which makes then unique
in terms of medical intervention (Taylor, R. S, 2014). Annie Javier and colleagues form the Sainte
Justine University Health Center in Canada investigated the use of probiotics to reduce the
incidence of NEC. They reported great success with nearly a 50% reduction in NEC incidence
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(Janvier, 2014). Janvier et al., (2014) reports using a commercially available probiotic:
FloraBABY. The researchers reported that this probiotic cost a mere 11 cents per day. In this
particular study, the average length of treatment was 24 days. Therefore, the cost per infant was
only $2.51(Janvier et al., 2014).
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Purpose
The purpose of this review is to evaluate the current research findings regarding the
potential for probiotics to prevent NEC in premature (<37 weeks gestation) neonates admitted to
the neonatal intensive care unit (NICU). A literature review was performed to examine the
current evidence. Probiotic strands will be identified that either decrease, increase or produce no
effect on the reduction of NEC, and the findings will be discussed.
The secondary purpose of this research is to make recommendations for current practice
and future practice based on the findings in this study. The final purpose of this study is to make
recommendations for future research based on the findings in this study.
Current studies lack consistency in their choice and combinations of probiotics. These
methodology differences have made it difficult to determine the most beneficial probiotic
supplement to premature neonates. Therefore, the overall purpose of this research is to identify
the probiotic strand or combination of probiotic strands that have the highest potential for
decreasing the incidence of NEC in premature neonates.
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Method
The focus of this comprehensive literature review will examine the effectiveness of
probiotics in decreasing the incidence of NEC in premature neonates. Information will be
obtained from CINAHL plus full text, Science Citation Index, Science Direct, Medline,
Academic One file, PsychINFO, EBSCOhost databases, and PUBMED to determine research,
which has been conducted, and the extent probiotics have shown to be effective. A scholarly
search of these databases will be conducted using the key words enterocolitis, Necrotizing*/PC
OR NEC* AND probiotics*. Literature criteria for this comprehensive review will consist only
of randomized control trials (RCTs) and quasi-randomized trials, peer-reviewed articles, research
articles, and articles written in the English Language no earlier than 2005. Population criteria for
this literature review will consist of neonates that are premature (<37 weeks gestations).
Neonates being fed breast milk, formula or a mixture of both will be eligible for inclusion in this
review. Additionally, probiotic supplementation must have commenced prior to the corrected
gestation of 40 weeks. This literature review will exclude data on neonates that have prior
genetic anomalies, gastrointestinal malformations, and/or prior diagnosis of NEC based on Bell’s
criteria. After applying exclusion criteria, 9 articles remained for this review.
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Figure 2: Method

199 articles were
identified

4 articles in a foreign
language were
eliminated

195 articles remained

5 repeated articles
were eliminated

190 articles remained

96 did not answer the
question

94 articles remained

87 articles eliminated
due to study design
not meeting inclusion
criteria

9 articles remained
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Findings
The literature review returned over 12 strains of probiotics that have been studied to
determine their effectiveness in preventing necrotizing enterocolitis. Staggering variances in
methodologies between the studies created a problem when trying to identify a clinically
significant approach to reduce the incidence of NEC. To better organize and discuss the
numerous strains studied they have been divided into three categories that include
Bifidobacterium species combined with Lactobacillus species, Lactobacillus species used alone,
and Saccharomyces species. Within these three categories the research articles are compared
based on: incidence of NEC, participant demographics, specific type and strength of probiotic
and finally, the timing of the introduction, duration of administration and feeding regimes. Each
section highlights evidence that shows how a particular species of probiotics may or may not
prevent NEC.
Bifidobacterium Species combined with Lactobacillus Species
The literature review returned 3 research studies that met the inclusion criteria, which
investigated the combined use of Bifidobacterium species and Lactobacillus species in terms of
reducing the incidence of NEC.
Incidence of NEC
Both Lin et al., (2008) and Braga et al., (2011) found a statistically significant reduction
in the incidence of NEC. Lin et al., (2008) reported that only 1.8% of the infants in the study
group developed NEC, whereas 9.2% of infants in the control group developed NEC. With a pvalue of 0.002, this was an incredibly significant decrease despite the potential center variations
this study encountered. Likewise, Braga et al., (2011) reports similar results with 0% of
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participants in the study group developing NEC versus 3.6% in the control group. With a p-value
of 0.05 this is also statistically significant.
The only study included in this review, which investigated the combined effects of
Bifidobacterium species with Lactobacillus species, that did not report a significant decrease in
the incidence of NEC was a double-blind, randomized clinical trial undertaken by FernandezCarrocera et al., (2013). Although there was a decrease in NEC in the study group, 8% versus
16%, the p-value was 0.132 and therefore these results, while clinically significant are not
statistically significant (Fernandez-Carrocera et al., 2013). It has been shown through molecular
studies that in the healthy gut of a breastfed infant Bifidobactrium species can represent
anywhere between 60% and 90% of the total fecal microbiota. Therefore, these results can
possibly be attributed to the use of 4 Lactobacillus strains and only 1 Bifidobactrium stain. This
specific combination does not mimic the microbiota of a healthy infant (Lin et al., 2008).
Population
The number of infants in the studies reviewed ranged from 150 to 434. Larger sample
sizes carry more weight than small sample sizes, however small sample sizes are acceptable as
when a power analysis is conducted to determine the minimal number of participants needed to
produce valid results. A power analysis was done in all three studies to ensure the minimum
participant number was met. However, in the Braga et al., (2011) trial, the research was
discontinued after one year rather than continuing the originally planned 2-year period of time
due to the trial producing clear benefits in the probiotic group. For this reason, Braga et al.,
(2011) did not met the minimum participant number of 282 in each group which weakens the
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validity of their results. By comparison, both Lin et al., (2008) and Fernandez-Carrocera et al.,
(2013) met the minimum participant requirement.
Lin et al., (2008) was the only study of this entire literature review that categorizes its
results based on birth weight. This helps to identify the true effects of probiotics on the extreme
low birth weight infants (ELBW) which is any infant weighting less than 1000g at birth.
Unfortunately, Lin et al., (2008) failed to stratify its participants based on birth weight during the
randomization of its participants. This caused the study group to have a significantly lower
average birth weight when compared to the control group (there were 33 infants weighting less
than 750g in the study group and only 18 infants weighing less than 750g in the control group).
This lower birth weight average in the study group puts the participants at a greater acuity and
therefore increased risk of NEC than those infants in the control group. Despite this, there was
still a significant reduction in the incidence of NEC.
Infants were excluded from all three trials if they had major congenital malformations
such as congenital intestinal atresia or gastroschesis, previously diagnosed life-threatening
chromosomal abnormalities, or severe asphyxia. Lin et al., (2008) included additional exclusion
criteria such as exclusive formula feedings and infants who had been fasted for greater than 3
weeks. Clinical similarities in all three trials made it easier to accurately compare acuity of the
participants.
Inclusion criteria of <1500g birth weight and <32 gestational age at birth was consistent
between the three trials however, the average birth weight and gestational age varied. Gestational
age ranged from 29.3 weeks (Braga et al., 2011) to 31.1 weeks (Fernandez-Carrocera et al.,
2013). Lin et al., (2008) did not specify the average gestational age of the participants, they
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simply stated that all infants were less than 32 weeks gestational age. Birth weight ranged from
an average of 1,053g (Lin et al., 2008) to 1,173g (Braga et al., 2011).
Specific Type and Strength of Probiotic
There were various forms and doses of Bifidobactrium and Lactobacillus administered in
the studies reviewed. Fernandez-Carrocera et al., (2013) even added one strain of streptococcus
into the probiotic mix. The only two probiotic types seen in two studies were L. acidophilus
(Fernandez-Carrocera et al., 2013; Lin et al., 2008) and L. casei (Fernandez-Carrocera et al.,
2013; Braga et al., 2011). More over two of the three studies investigated the reduction of NEC
using two strains of probiotic (Lin et al., 2008; Braga et al., 2011) while, Fernandez- Carrocera et
al., 2013) employed the use of six various probiotics strains, four of which were Lactobacillus
strains. The vast difference in type of probiotic studied makes it near impossible to identify
which specific strain combination of Bifidobactrium and Lactobacillus create the greatest
reduction in NEC incidence.
The dose presentation between the three studies also varies greatly. Although all three
trials measure the probiotic by CFU’s the dosing was random and ranged from 3.5 x10^7 (Braga
et al., 2011) to 1x10^9 (Lin et al., 2008; Fernandez-Carrocera et al., 2013) and everywhere in
between. The only consistency in dosing was in Lin et al., (2008) and Fernandez-Carrocera et al.,
(2013) where 1x10^9 CFU’s of L. acidophilus are used. This inconsistency of dosage made it
impossible to compare the doses of various probiotics.
Timing of the Introduction, Duration of Administration and Feeding Regimes
The introduction time, length of administration and feeding regimes were different for
each study. Probiotic supplementation was started when the first enteral feeds were started
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(Fernandez-Carrocer et al., 2013; Lin et al., 2008) or on the second day of life (Braga et al.,
2011). Furthermore, the duration of administration ranged from 30 days (Braga et al., 2011) to
until 6 weeks (Lin et al., 2008) to until discharge or death (Fernandez- Carrocera et al., 2013).
The feedings regimes were comparable between the three studies. Lin et al., 2008 and
Braga et al., (2011) were both very detailed in the protocol for advancing feeds and neither study
advanced feeds more than 20mL/kg per day. However, Braga et al., (2011) did not stop probiotic
administration during times of feeding intolerance like Lin et al., (2008) and FernandezCarrocera et al., (2013). All three studies allowed the use of human milk and/or fortified preterm
formula for feeding however, Braga et al., (2011) specifically fed the infants breast milk until the
third week of life and then introduced fortified preterm formula to their diet. This inconsistent
milk forms between these studies makes it difficult to analyze the effects of probiotics.
Lactobacillus Species
This literature review returned two articles that met the inclusion criteria, which focused
on Lacrobacillus species as the single agent of investigation.
Incidence of NEC
Both Sari et al. (2011) and Oncel et al. (2014) found that the use of lactobacillus species
produced no significant effect on the incidence of necrotizing enterocolitis stage 2 or greater.
Oncel et al., (2014) reported the rate of NEC amongst the probiotic group participants to be 4%.
This is only slightly reduced from the control group which had a NEC rate of 5%. With a p-value
of 0.63, this reduction in NEC cannot be considered statistically or clinically significant. These
results mirror the findings in the Sari et al., (2011). Sari et al., (2011) reported a NEC incidence
rate of 5.8% in the study group and 9% in the control group with a p-value of 0.447. Like the
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Oncel et al., (2014) study these are not statistically significant results. Sari et al, (2011) attributes
the lack of change in incidence of NEC to the small population size and the interference of
intestinal blood flow caused by umbilical venous catheters that were in place significantly longer
in the study group than the control group.
Population
The researchers in both of the lactobacillus studies examined in this literature review
excluded infants that were at an increased risk for NEC such as infants exposed to prenatal
steroids, prolonged rupture of the amniotic membranes and asphyxia (Oncel et al., 2014; Sari et
al., 2011). The demographic and clinical similarities between the participants of the two studies
created an advantage for this review. Both research studies used event analysis with an α-error
set at 0.05, the β-error set at 0.2 with an absolute reduction in incidence of NEC of 50%. Sari et
al., (2011) determine that to verify the hypothesis the minimum number of participants needed in
each arm of the study was 111 infants. There were 110 infants in the probiotic group and 111
infants in the control group therefore, the minimum number of participants was not achieved for
the probiotic group which reduces the validity of the results presented in this study. Oncel et al.,
(2014) determined that the minimum number of participants in each arm needed to be 190. This
minimum was achieved with 200 infants in both the study and control group thereby
strengthening the validity of results in this study.
The participants in the Oncel et al., (2014) were slightly younger with an average
gestational age of 28.0 weeks versus 29.6 gestational weeks in the Sari et al., (2011) participants.
Likewise, the participants in the Oncel et al., (2014) study were also smaller than the Sari et al,
(2011) participants with an average birth weight of 1,059.5g versus 1,254.5g, respectively. This
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near two week and 200g difference between the participants of the two studies makes it difficult
to comparatively analyze the results.
Specific Type and Strength of Probiotic
The specific strains of probiotic investigated in the Oncel et al., (2014) study and the Sari
et al., (2011) study differed from one another. Oncel et al., (2014) supplemented feedings with L.
reuteri and Sari et. al, (2011) supplemented feedings with L. sporogens, which was the first
study to examine L. sporogens. Unfortunately, there is a deficit in research examining the
effectiveness of these two strains of Lactobacillus in reducing NEC. For this reason, it is
impossible to say which of these two strains carries the greatest benefit. However, it is thought
that the main action of all Lactobacillus species is to aid and regulate the host- defense
mechanisms of the intestines. It is possible then, that all lactobacillus species will produce
similar results, in regards to decreasing NEC, as these two studies but further research is needed
to confirm the validity of this hypothesis.
In terms of probiotic strength, the presentation of dose strength was the same which made
it easy to decipher the equality of the strengths. Oncel et al., (2014) supplemented feedings with
100,000,000 CFU and Sari et al., (2011) supplemented feedings with 350,000,000 CFU. The
supplementation in the Sari et al., (2011) study is significantly larger which makes it peculiar
that there was no significant reduction in NEC incidence. This study design would need to be
repeated in further research to determine the variables attributing to the insignificant NEC
reduction.
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Timing of the Introduction, Duration of Administration and Feeding Regimes
Introduction time, administration duration and feedings regimes were comparable in both
lactobacillus studies. Probiotics were introduced with the first feed and when the participants
were clinically stable (Oncel et al., 2014; Sari et al., 2011). However, details as to the exact day
of first feed was not reported. For all participants in both studies, probiotics were administered
until discharge or death. Furthermore, both studies started the feeding at a rate of 10-20mL/kg
per day and restricted the advancement of feeds to no more than 20mL/kg per day. Also for
participants in both study designs, feedings were stopped if there were two or more signs of
feeding intolerance and held until the feeding intolerance resolved (Oncel et al., 2014; Sari et al.,
2011).
The methodology differences between Oncel et al., (2014) and Sari et al., (2011)
appeared in the mechanism of administration of probiotics. Oncel et al., (2014) administered the
probiotic supplementation by placing 5 drops of L. reuteri in an oil based suspension on the back
of the oropharynx of the infants while Sari et al., (2011) added the L. sporogenes to the milk
feeds. There was no mention by Oncel et al., (2014) as to how this unique administration could
have affected results nor has this study been repeated. For this reason, it is impossible to
determine if the two administration methods cause variable results.
Saccharomyces Species
Two studies investigating the use of Saccharomyces species met the inclusion criteria for
this literature review.
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Incidence of NEC
Neither the study by Demirel, Erdeve, Celik & Dilmen (2013) nor the study by Serce,
Benzer, Gursoy, & Ovali (2013) reported any decrease in NEC in the infants studied. Demirel et
al. (2013) was the first randomized, controlled trial to investigate the use of S. boulardii as a
preventative method to NEC. This study reported the rate of NEC in the study group as 4.4%
which is just slightly lower than the rate of 5.1% in the control group however, this was not a
statistically significant decrease with a 95% confidence interval and p-value of 1 (Demirel et al.,
2013). Additionally, in both the study and the control group there were two cases of NEC stage 3
(severe NEC).
Population
The number of infants in the studies investigating Saccharomyces species were rather
similar with 271 in the Demirel et al. (2013) study and 208 in the Serce et al. (2013) study.
Through event rate analysis Serce et al. (2013) was able to determine that in order to verify their
hypothesis they would need a minimum of 104 in the study group and 92 in the control group.
With 104 in both the study and control group they met the minimum population size which
strengthens the validity of the results presented in this study (Serce et al., 2013). Likewise,
Demirel et al. (2013) determined through event analysis that the minimum population size for
both the study and control arm was 111. This minimum population size was met with 135 in the
study group and 136 in the control group therefore, the validity of the results reported is
strengthened. Both Demirel et al. (2013) and Serce et al. (2013) used an α-error of 0.05 and a βerror set at 0.2 with an absolute reduction in the incidence of NEC of 50%.
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In terms of average gestational age and weight of the participants, both the Demirel et al.
(2013) and the Serce et al. (2013) studies were comparable with average gestational ages of 29.3
weeks and 28.7 weeks respectively, and average weights of participants at 1,147.5g and 1,144g,
respectively. Furthermore, the demographics between the study participants were similar with
both research groups excluding infants with clinical signs that put them at an increased risk for
NEC.
Specific Type, Dose and Strength of Probiotic
Both Demirel et al. (2013) and Serce et al. (2013) investigated Saccharomyces boulardii.
The difference between these two studies is in the dosage and strength of probiotic. Demirel et
al. (2013) investigated S. boulardii at a strength of 250mg per day while Serce et al. (2013)
investigated this probiotic strain at 50mg/kg/12 hour. Adjusting this to show comparisons this is
100mg/kg per day. The average weight in kg between both the study and control group was 1.14
kilograms (Serce et al., 2013). Therefore, the average dose of probiotic given to the infants in
this study was roughly 114mg per day. Less than half the dosing given to the study participants
in the study by Demirel et al. (2013).
The strength of S. boulardii used in these two studies was difficult to compare due to the
differing presentation of the strengths. Demirel et al. (2013) reports using 5 billion colony
forming units (CFU), while Serce et al. (2013) used a numerical value of 0.5 x 109 cell/kg/dose.
This made it impossible to compare the strengths used in these two studies.
Timing of the Introduction, Duration of Administration and Feeding Regimes
The timing of probiotic introduction was slightly different for these two studies. Both
studies started probiotic supplementation at the time feedings commenced. However, Demiral et
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al. (2013) commenced feedings 48 hours after birth whereas Serce et al. (2013) commenced
feedings at only 24 hours after birth. Although a 24-hour difference in the commencement of
feedings does not appear to be clinically significant, in the life of a preterm infant, 24 hours is
very clinically significant. Unfortunately, neither study comments as to why this particular
initiation time was chosen and makes no mention about the participants being clinically stable at
the time feedings commenced.
There were methodology similarities between Serce et al. (2013) and Demiral et al.
(2013) in regards to the duration of administration and feeding regimes. Both studies continued
probiotic supplementation until either discharge or death of the infant. Also, both studies began
feeding each participant with 10-20mL/kg/day of either fortified formula or human breast milk.
The variation between the studies appeared in the method of advancing feedings. Demiral et al.
(2013) gave very scarce guidelines as to how the feedings were advanced, simply stating that the
advancement of feeds did not exceed 20mL/kg/day. By comparison Serce et al. (2013) listed
very systematic methods as to how the feedings were increased based upon the infant’s weight:
10mL/kg/day for infants weighing <750g; 20mL/kg/day for infants weighing 750-1250g; and
30mL/kg/day for infants weighing 1250-1500g. Furthermore, Serce et al. (2013) added a fortifier
to the human milk once the goal feeding of 100mL/kg/day was achieved. Demiral et al. (2013)
makes no mention of additional fortifiers added to feedings.
Although the differences between these two studies are not extreme, the use of both
breast milk and fortified formula amongst the participants makes evaluating the benefits of
probiotics difficult.
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Other Considerations
Rate of Sepsis
Although the study performed by Oncel et al., (2014) investigating the use of L. reuteri
showed no significant reduction in the rate of NEC there was a statistically significant reduction
in the rate of sepsis between the study group and the control group. With a p-value of 0.041, the
rate of sepsis in the study group was only 6.5% whereas in the control group there was 12.5% of
participants with proven sepsis (Oncel et al., 2014). Comparatively, the rate of culture-proven
sepsis in the Sari et al., (2011) study was not statistically lower in the study group (26.4%) when
compared with the control group (23.4%) with a p-value of 0.613. It is difficult to determine the
cause of the drastically different results in sepsis occurrence due to the many inconsistencies
between the two studies including but not limited to the specific strain of Lactobacillus
investigated. More importantly however, in both studies, none of the positive blood cultures
grew Lactobacillus bacteria. Therefore, the risk of sepsis as it relates to Lactobacillus
supplementation appears extremely low.
Despite the Demiral et al. (2013) study showing S. Boulardii at a dose of 250mg/day
ineffective in preventing NEC, their study did report a statistically significant reduction in the
rate of clinical sepsis. With a rate of 34.8% in the study group and 47.8% in the control group
with a 95% confidence interval. However, more importantly is that none of the positive blood
cultures grew S. Boulardii. By comparison, Serce et al. (2013) reported no significant difference
in the rate of sepsis between the probiotic study group and the control group.
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Rate of Feeding Intolerance
Similar results were also reported in both the Lactobacillus studies. A statistically
significant reduction was observed in feeding intolerance for both the Oncel et al., (2014) and the
Sari et al., (2011) studies were reported: 28% vs. 39.5% with a p-value of 0.015 and 44.5% vs
63.1% with a p-value of 0.006, respectively.
Similarly, to the rate of sepsis, Demiral et al. (2013) reported that S. Boulardii at a rate of
250mg/day can provide a statistically significant decrease in feeding intolerance for premature
infants. In the probiotic group, only 22.9% of the infants had at least one episode of feeding
intolerance whereas 48.1% of the infants in the control group had at least one episode of feeding
intolerance. By comparison, Serce et al. (2013) reported no significant difference in the rate of
feeding intolerance or time to reach full enteral feedings between the study group and the control
group.
Duration of Hospitalization
Amongst the studies investigating Lactobacillus species, a significant difference in length
of hospital stay was reported from the Oncel et al., (2014) study with the probiotic group
participants having an average stay of 38 days and the control group participants staying an
average of 46 days in the hospital with a p-value of 0.022. The second study investigating
Lactobacillus, Sari et al., (2011), did not have any mention of hospital stay amongst its
participants.
The research studies investigating S. Boulardii by Serce et al. (2013) and Demiral et al.
(2013) both reported that S. boulardii supplementation had no significant effect on the length of
a neonate’s hospital stay.
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Summary
Table 1: Bifidobactrium combined with Lactobacillus Species
Author

Probiotic Used

Dose

Sample size

Length of
treatment

Gestation
at initiation
of
treatment
2 days post
birth

Increase
or
decrease
of NEC
Decrease

Braga
et.al., 2011

B. breve
L. casei

3.5 · 107 to 3.5·
109 CFU;

231 babies <1500g
(119 probiotics and
112 control)

Once daily for
30 days

FernándezCarrocera
et. al, 2013

B. breve
B. bifidum
B. infantis
B. longum
L. rhamnosus GG

2 x 10^9 CFUs

294 participants in the
study group; 317
participants in the
control group

Janvier, A;
Malo, J., &
Barrington,
K.,
2014Javier,

L. acidophilus
L. rhamnosus
L. casei
L. plantarum
B. infantis
Streptococcus
thermophillus

1g per day
diluted in 3ml of
milk

Lin et. al.,
2008

B. bifidum
L. acidophilus

10^9 CFU and
10^9 CFU
respectively
@125mg/kg/dose

Once daily
until 34 weeks
gestation.

Starting
with the
first enteral
feeding

Decrease

150 babies (75 and
75) <1500g

Once daily. No
other specifics
noted.

Starting
with the
first enteral
feeing

Decrease

6 (8%) versus
12 (16%) in the
control group
but the
difference was
not statistically
significant.
(p=0.132)

434 babies <1500g
<34 weeks

Twice daily for
6 weeks

Starting
with the
first enteral
feeding

Decrease
of NEC

≥stage 2
NEC/Death:
P.002

30

Incidence of
NEC: Study
vs. Control
0 in study group
and 4 in control
group.
P .05
Probiotic: 5.4%
Placebo: 9.8%
(P < .02)

Table 2: Lactobacillus used alone
Author

Probiotic
Used

Dose

Sample Size

Length of
Treatment

Oncel
et. al.,
2014

L. reuteri

100 million CFU/day
(5 drops) lyophilized

400 babies
with gestation
≤32 weeks and
birth weight
≤1500g

Daily until
discharge

Sari et.
al,
2011

L. sporogenes

350 000 000 CFU
1ml suspension was
added to breast milk
or formula

221 babies
with gestation
of <33 weeks
or birth weight
of <1500g
(110 in the
study group
and 111 in the
control group)

Daily Until
discharge
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Gestation
at
initiation
of
treatment
Starting at
first
feeding

Increase or
Decrease of
NEC

Incidence of NEC:
Study vs Control

No effect

There was no
statistically significant
difference between
groups in terms of
frequency of NEC
stage ≥2 (4% vs 5%;
p=0.63) or overall
NEC or mortality rates
(10% vs 13.5%;
p=0.27)

Once they
could
enterally
feed and
then
starting at
first
feeding

No effect

The incidence of NEC
was not significantly
lower in the probiotics
group than in the
control group (5.8 vs
9%, respectively; P 1⁄4
0.447).

Table 3: Saccharomyces used alone
Author

Probiotic Used

Dose

Sample Size

Length of
Treatment

Demirel et.
al., 2013

S. boulardii

250 mg/
day of 5
billion
CFU

217 babies with
gestation ≤ 32
weeks and birth
weight
≤1500g (135 in the
study group and
136 in the control
group)

Once daily
until
discharge

208 babies with
gestation ≤32 and
birth weight ≤1500
g (104 in the study
group and 104 in
the control group)

Every 12
hours until
discharge

Serce et.
al., 2013

S. boulardii

50 mg/kg
every 12
h
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Time of
initiation of
treatment
Once they
could be
enterally
fed. Starting
with first
feed.

Increase or
decrease of
NEC
No
significant
effect

Once they
could be
enterally
fed. Starting
with the
first feed

No effect

Incidence of NEC:
Study vs Control
4.4% vs. 5.1%, 95%
CI, !0.65–5.12; p =
1.0)
However, it did
improve feeding
intolerance and
reduced risk for
sepsis

The incidence of
stage ≥2 NEC was 7
(6.7%) both in the
control and study
group, and it did not
reach statistical
significance (p = 1)

Discussion
Necrotizing enterocolitis remains one of the most devastating pathologic processes faced
by premature infants with an unchanging incidence rate of 7%-14% and significant mortality of
up to 30% (Deshpande et al., 2010). It is known that the pathogenesis of NEC involves a series
of factors, with prematurity (less than 37 weeks gestation) consistently documented as one of the
most influential (Braga et. al, 2011; Lin et. al, 2008). Aside from the high incidence and
mortality rate associated with NEC, there is also an increased need for surgery to remove the
areas of necrotic bowel and long-term ramifications, such as short bowel syndrome and its
associated consequences of recurrent sepsis and total parenteral nutrition (TPN) dependence
(Deshpande et al., 2010). It has been documented that surgically treated NEC, typically seen in
Stage 3 or “advanced NEC” can prolong neonates’ hospital stay up to 60 days and cause longterm neurodevelopmental impairment (NDI) (Deshpande et al., 2010; Schulzle S.M., Desphande
G.C., & Patole SK, 2007). NDI encompasses cerebral palsy, bilateral blindness or bilateral
deafness (Reese, C.M., Pierro, A., & Eaton, S., 2007). In the study by Schulzle et al. (2007) it
was found that neonates with definite NEC (Bells stage 2 or greater) were significantly more at
risk for long-term NDI when compared to infants who did not develop NEC with an odds ratio of
1.82. Factors causing NDI in premature infants are complex. Brain development continues into
the second and third trimester. Therefore, infants born premature have a deficit in neuronal
maturation which increases the risk for long-term NDI (Reese, C.M. et al., 2007). Proper
nutrition is essential for the continued growth of the brain after birth. Nutrition becomes
problematic for the infants with NEC considering NEC is associated with increased rates of
feeding intolerance (Janvier, 2014). The issue of nutrition is furthered in the infant whose NEC is
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treated surgically. When sections of gangrenous bowel are removed surgically due to NEC the
infant has smaller gastrointestinal surface area to absorb necessary nutrients (Reese, C.M. et al.,
2007). This is known as short bowel syndrome.
The microbiota within the gastrointestinal system must remain balanced between healthy
gut bacteria, such as Bifidobactrium and Lactobacillus, and pathologic bacteria, such as
staphlococcci, enterobacter, enterococci, and clostridia. If this balance is disturbed, for example
by an over proliferation of pathologic bacteria, disease such as NEC can occur (Lin et al., 2008).
It has been hypothesized that preterm infants fed probiotic supplements containing
bacteria found within the healthy newborn gut would have a decreased incidence of NEC (Braga
et al., 2011; Fernandez-Carrocera et al., 2013; Janvier, 2014; Lin et al., 2008) . There is strong
evidence supporting the benefits of prophylactic use of probiotics but more research is necessary
to support the practice of routine probiotic supplementation. Among the literature reviewed there
was a lack of consistency in study design (probiotic strain, dosage, feeding protocol, and
duration) and this has led to debate about the effectiveness of probiotics in preventing NEC as
some studies (Demirel et. al., 2013; Serce et. al., 2013) show no reduction in NEC, while others
report astounding reduction (Braga et. al., 2011; Javier et al., 2014; Lin et. al., 2008).
Inconsistency in feeding protocol, human milk versus formula, may be attributed to reports, such
as by Guaraldi, F. & Salvatori, G. (2012), stating that the type of milk fed does not significantly
alter the gut ecosystem, and therefore causing researchers to believe the type of milk does not
alter results.
The strains investigated in this literature review included Bifidobactrium strains
combined with lactobacillus strains, lactobacillus strains used alone and Saccharomyces strains
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used alone. These three categories of probiotic species were investigated because they were the
most frequently studied among current research (Deshpande et al., 2010). Despite the narrowed
categories and the exclusionary criteria used in this review, a total of 12 different strains are
represented between the studies. While there is some overlap in probiotic strains, little
similarities in the duration of administration/administration parameter, time of initiation, or
combination of strains was found. It is important to note that the mechanism of action of
probiotics is strain specific (Serce et al., 2013). With no two studies matching in probiotic strains
investigated a significant limitation was placed on the ability to compare studies in this review.
Bifidobactrium combined with Lactobacillus
It is well known among health professionals versed in the intestinal health of infants that
the healthy newborn’s intestines are colonized primarily by species of Bifidobactrium bacterial
species. In fact, molecular studies show that 60%-90% of gut colonization in a healthy newborn
is by Bifidobactrium species specifically, Bifidobactrium bifidum, Bifidobactrium longum and
Bifidobactrium breve (Lin et al., 2008). The knowledge of this provides a clear rationale as to
why the studies using a combination of Bifidobactrium and Lactobacillus strains (Braga et al.,
2011; Fernandez-Carrocera et al., 2013; Janvier, 2014; Lin et al., 2008) are reporting a reduction
in NEC among their study participants. All but one (Fernandez-Carrocera et al., 2013) of the
research studies using the combination of Bifidobactrium and Lactobacillus found that there was
a statistically significant decline in the incidence of NEC when these species of probiotics were
added to feedings. More specifically, B. breve appears to be the most frequently studied
Bifidobacrium strain studied due to its high affinity with the immature intestine and its large
presence in the gut of a healthy newborn (Deshpande et al., 2010).
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Among the studies investigating Bifidobactrium and Lactobacillus, (Braga et al., 2011;
Fernandez-Carrocera et al., 2013; Janvier, 2014; Lin et al., 2008) three of the four studies
reported a statistically significant reduction in NEC. This suggests that the use of probiotics,
specifically Bifidobactrium and Lactobacillus may prevent the occurrence of NEC stage 2 and
greater. The American Academy of Pediatrics (Section on Breastfeeding, 2012) recommends
exclusively feeding preterm infants human breast milk, citing that one of the benefits is the
reduced incidence of NEC. While human milk contains oligosaccharides that are beneficial to the
neonatal gastrointestinal system, and has even shown to reduce NEC (Lin et al., 2008), feeding
human milk alone cannot completely eradicate the incidence of NEC (Deshpande et al., 2010).
This is attributed to interleukin 10 deficiency in preterm newborns. As previously mentioned,
Bifidobactrium species and Lactobacillus species have both been shown to induce interleukin 10
production (Lin et al., 2008). Therefore, probiotics and human milk may work synergistically to
reduce the incidence of NEC (Lin et al, 2008). This hypothesis would need to be studied further
due to a scarcity of research investigating the use of probiotics in conjunction with exclusively
human milk fed preterm infants.
Despite the promising results with Bifidobactrium and Lactobacillus, the number of
studies that have evaluated the association of these two probiotics remains extremely low (Braga
et al., 2011) and not a single study design has been repeated. As a result, health professionals are
hesitant to implement probiotic supplementation into standard practice (Braga et al., 2011).

36

Lactobacillus Species Used Alone and Saccharromyces Species Used Alone
As previously stated, this literature review supports prior meta-analyses in showing that
when only one species of probiotic is used alone, there is no reduction in the incidence of NEC
(Deshpande et al., 2010). The studies that investigated Lactobacillus species or Sacharromyces
showed no significant reduction to NEC. It should be pointed out that Saccharromyces is actually
a yeast rather than a bacterium. Still considered a probiotic, yeast such as Saccharromyces
species have been shown to antagonize both other yeasts and bacteria in a similar fashion as
bacterial probiotics (Serce et al., 2013). Despite animal studies showing the potential for
Saccharromyces species to inhibit pro-inflammatory mediator release, there was no reduction of
NEC seen in this review (Serce et al., 2013). These results may be attributed to a differing
immune response by the gut mucosal cells due to the substantial difference in cell wall structure
between yeast and bacteria (Serce et al., 2013). This however, is just a hypothesis and further
studies investigating the use of yeast would need to be conducted. These two probiotic species
cannot be completely dismissed however. Both Lactobacillus and Saccharomyces studies
showed that there was a significant reduction in the rate of feeding intolerance (Demirel et al.,
2013; Oncel et al., 2014; Sari et al., 2013). For improved overall prognosis of this high-risk
population, it is essential to establish optimal enteral nutrition as early as possible in the postnatal
life (Deshpande et al., 2010). For this reason, supplementing feedings with these two species of
probiotics would not be futile if its purpose was to enhance enteral nutrition via improved gastric
emptying, and gut barrier function (Deshpande et al., 2010).
Results in terms of sepsis reduction and overall hospital stay were sporadic between the
Lactobacillus and Saccharomyces studies and therefore it is inconclusive whether these species
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can produce a significant reduction in these two events. The variation in results could be
attributed to the heterogeneity in study designs (Deshpande et al., 2010). The inconsistent
reduction in sepsis incidence seen in this review may also be attributed to the multiple sources of
entry for various pathogens such as endotracheal tubes, central venous catheters, lipid infusions
and TPN (Deshpande et al., 2010). Therefore, probiotics may have the ability to reduce the
presence of coagulase-negative Staphylococcus (CONS), which is primarily found in the gut, but
it it less likely that probiotics could overcome the burden of pathogens from these other entry
points (Deshpande et al., 2010). It is reassuring however, that there were zero sepsis related
deaths and zero probiotic related sepsis occurrences in this literature review (Braga et al., 2011;
Demireal et al., 2013; Fernandez-Carrocera et al., 2013; Janvier, 2014; Lin et al., 2008; Oncel et
al., 2014; Sari et al., 2011; Serce et al., 2013)
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Conclusion
Necrotizing Enterocolitis is a severe life threatening gastrointestinal disease that often
leads to death for premature neonates. In order to reduce the mortality rate associated with this
disease it is vital to determine an effective preventative strategy . There is currently insufficient
knowledge regarding the precise etiology, disease process, or the long-term consequences of
NEC to prescribe a definitive preventative method. For this reason, research into the preventative
use of probiotics, among other interventions such as, mothers own milk, increased oxygenation,
prebiotics and steroids is ongoing. Furthermore, the use of probiotics as a preventative treatment
for NEC has not been thoroughly researched in the extremely premature infant population (<28
weeks gestation). Therefore, although the results are promising further research is needed before
the use of probiotics can be determined a safe prophylactic treatment for the generalized
premature population.
The consensus between all studies investigating the use of probiotics is that it is an
attempt to mimic the natural bowel colonization and microbiota of a healthy infant born full term
(Deshpande et al., 2010). Although the use of probiotics appears promising, it should be
highlighted that all of the studies included in this literature review reported NEC when it was
confirmed at stage 2 or greater according to Bell’s Criteria. This omits the early stages of NEC,
or “suspected NEC”. There is little to no research related to probiotics and their ability to prevent
NEC development in these early stages. While NEC stage 2 and greater is associated with the
greatest risk for mortality, NEC stage 1 still has the ability to cause morbid conditions with lifelong health consequences such as a distended abdomen (Braga et. al, 2011). It is possible that if
the confirmed outcome was expanded from “Confirmed NEC stage 2 or greater” to simply
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“NEC, including suspected NEC”, the effects of probiotics in reducing NEC incidence would be
less significant.
Considering the results vary among the species specific research designs it is impossible
to determine if there is a precise strain of probiotic more suitable to prevent NEC in the preterm
infant. Despite the variable results and large variety of probiotic strains, this literature review
further supports prior meta-analysis such as Deshpande et. al. (2010) that conclude that the
administration of only one probiotic strain (eg. only one Lactobacillus strain or one
Saccharomyces strain) is ineffective in reducing the incidence of NEC. By comparison, studies
investigating the use of two or more strains of probiotics used in conjunction saw a significantly
reduced incidence in the disease (Braga et al., 2011; Lin et al., 2008)
However, in conclusion, the great majority of research studies show a promising
correlation between the combined use of Bifidobactrium species with Lactobacillus species and a
decreased incidence in NEC for neonates born premature (Desphande et al., 2010).

40

Recommendations for Current Practice
Due to the financial costs and deadly nature of NEC in premature neonates it is
recommended that health care professionals discuss the potential benefits of probiotics with
caregivers. As seen in this literature review, the risk for sepsis as a result of probiotics is
extremely rare. There is also the added benefit of increased nutrition due to the reduced rate of
feeding intolerance seen in infants given probiotics. Therefore, probiotics used as a prophylactic
treatment for NEC comes with little risk other than cost of the probiotic itself which, in
comparison to the cost of NEC treatment, is minimal (Janvier et al., 2014). To ensure that this
discussion occurs routinely it may be beneficial to provide an informational handout to parents or
caregivers of premature neonates. This informational handout could educate parents on what
NEC is and why their preterm newborn is at an increased risk of developing NEC. This would
include how their preterm infant’s gut microbiota differs from that of a term newborn. The
informational handout would also need to include the purpose of probiotics, which is to
introduce “good” bacteria that mimics the bacteria seen in term newborns, and how the
supplementation of probiotics might prevent the occurrence of NEC. It would have to be stressed
however, that research is yet to be definitive on the most beneficial strain, dosage or
supplementation method. That there is simply a strong correlation between probiotic
supplementation and a reduction in NEC incidence. Therefore, health care professionals could
not guarantee the prevention of NEC while discussing this preventative approach.
In addition to suggesting the use of probiotics there are other preventative measures that
that can incorporated in the NICU setting. This includes the continued use of antenatal
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corticosteroids and exogenous surfactant to aid in lung develop which subsequently increases
oxygenation of organs including the gastrointestinal tract.
Finally, it would be beneficial that, when possible, strict feeding protocols of human milk
feeds only be implemented in current practice. This implementation can be accomplished by
supporting mothers who choose to breast feed if their infant is able. This also includes supporting
the mother during the time when a baby cannot adequately breast feed, by supporting the use of
the breast pump and milk storage. Human breast milk differs from formula milk in the nutrient
composition but more importantly human milk contains growth factors, not found in formula,
that aid in the maturation of a newborn’s gut epithelial cells and subsequent peristalsis and
immunologic defenses necessary to maintaining a healthy gut ecosystem (Guaraldi F. &
Salvatori G., 2012).
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Recommendations for Future Practice
As research continues to be conducted pointing towards the benefits of Bifidobacterium
species and Lactobacillus species for NEC prevention, it is recommended that health care
professionals begin using these probiotic strains as supplementation routinely on all neonates
born before the 37th week of gestation or born weighing less than 1500g. It may be interesting to
note that since Japan has introduced the routine use of probiotics to prophylactically treat NEC,
their NEC incidence rate has decreased to approximately 1% (Taylor, R. S., 2014).
Probiotic supplemented feedings would slightly increase the cost of routine care.
However, the objective is to reduce the long term treatment costs associated with NEC and
subsequently decrease the length of hospitalization for NICU patients. If incidence of NEC is
reduced, the length of hospitalizations, cost of treatment for NEC and overall health of the
neonate can improve. Current research shows that supplementing feedings with these probiotic
strains produce a negligible risk for sepsis, and therefore has a beneficial risk-benefit balance
(Taylor, R.S. 2014). The reality of the situation is that the gastrointestinal tracts of preterm
infants are going to become colonized. Therefore, it becomes a matter of what type of bacteria
that will colonize the GI tracts. The risk of an extremely rare case of sepsis occurring associated
with the administration of probiotics, which is easily resolved via antibiotics (Janvier et al.,
2014), should be weighed against the significantly larger risk accrued when an infant’s GI tract is
colonized by pathologic bacteria (Janvier et al., 2014).
Additionally, there is a strong correlation with improved feeding tolerance and the use of
probiotic supplemented feedings (Braga et al., 2011; Demiral et al., 2013; Oncel et al., 2014; Sari
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et al., 2011) along with a reduced hospital stay (Oncel et al., 2014). Therefore, the benefits
outweigh the cost.
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Recommendations for Future Research
This review has identified several probiotic strains researched to reduce the incidence of
NEC. It has also identified that the current research has vast inconsistences in methodology.
Even among research studies that look at similar probiotic strands, the other independent
variables such as number of colony forming units, time of initiation, and length of treatment vary
so significantly that there is not a single repeated study design. This hinders the growth of
knowledge on how to prevent NEC in NICU patients.
Therefore, it is important that going forward in the research of NEC prevention that study
designs shown to be successful, such as the study by Lin et. al in 2008, are repeated to validate
the effectiveness of these researcher’s methodology and validate the results. Only once variances
between independent variables are reduced will HCPs have a basis for how to move forward in
practice and prevention of this deadly disease process.
Due to the long-term consequences of NEC, such as short bowel syndrome, NDI, and
frequent sepsis, research investigating the long-term ramifications of NEC, specifically in these
areas, would greatly improve the overall knowledge of the pathogenesis of NEC. Additionally, as
the ability to care for preterm infants increases it would be wise to look into the effects of
prophylactic probiotic supplementation on extremely preterm infants (less than 28 weeks old).
Further research should also evaluate the effectiveness of incorporating additional
prevention strategies such as improving oxygenation and tissue perfusion, strict feeding
protocols that establish the use of human breast milk only, and slow advancements of enteral
feeds.
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Limitations
As previously mentioned, the relationship between the incidence of NEC and prematurity
is inversely related (Gephart et al., 2012). The typical neonate in a level III NICU is of high
acuity, often times extremely premature at less than 32 weeks gestation, presenting with
comorbidities, and significant genetic anomalies (Levels of Neonatal Care, 2004). The
participants in this literature review were all less than 32 weeks gestation however, the
exclusionary criteria was such that infants with genetic anomalies or gastrointestinal
comorbidities were excluded. Therefore, it can be concluded that this literature review contains
studies that did not always look at infants with the greatest risk for NEC. This is a limitation
because it is not applicable to the extremely premature infant with confounding morbidities and
therefore not generalizable to all NICU patients (Rohan & Wainwright, 2014).
Another limitation to this literature review was that the scarcity of research made it so
that no two studies were identical in probiotic strain, dosage or method of administration. It is
important to note that the mechanism of action of probiotics is strain specific (Serce et al., 2013).
Without repetition of probiotic strains investigated it is near impossible to determine with any
certainty a single strain or combination of strains that is most effective in preventing NEC.
Therefore, no definitive conclusion could be drawn as to which probiotic strain, dosage or
method was most beneficial.
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